Eli Lilly Earnings Call Recap: Retatrutide News
https://www.otplinks.com
7 Aug 59min
Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.
Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes i...
4 Aug 18min
Retatrutide Biologic Battle: The Story Gets Bigger
https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks understand.This breakdown cov...
28 Juli 20min
GLP-1 Showdown: Inside The High Stakes War over Patients
Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode...
22 Juli 27min
Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know
What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about obesity treatment.In this week...
14 Juli 31min
Compound GLP-1 Poll STUNS THE INTERNET!
What If We've Been Asking the Wrong Question?Patients say compounded GLP-1s are more effective than branded medications. Dave explains why the answer may have nothing to do with the drug itself, and e...
8 Juli 15min
How To Get $50 GLP-1
Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...
23 Juni 44min
What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) to break down the molecules, clinica...
16 Juni 1h 15min
